These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 20338549)
1. The potential use of Toll-like receptor agonists to restore the dysfunctional immunity induced by hepatitis C virus. Salem ML; El-Demellawy M; El-Azm AR Cell Immunol; 2010; 262(2):96-104. PubMed ID: 20338549 [TBL] [Abstract][Full Text] [Related]
2. Innate immunity and chronic immune activation in HCV/HIV-1 co-infection. Gonzalez VD; Landay AL; Sandberg JK Clin Immunol; 2010 Apr; 135(1):12-25. PubMed ID: 20100670 [TBL] [Abstract][Full Text] [Related]
3. Impaired cytokine response in myeloid dendritic cells in chronic hepatitis C virus infection regardless of enhanced expression of Toll-like receptors and retinoic acid inducible gene-I. Miyazaki M; Kanto T; Inoue M; Itose I; Miyatake H; Sakakibara M; Yakushijin T; Kakita N; Hiramatsu N; Takehara T; Kasahara A; Hayashi N J Med Virol; 2008 Jun; 80(6):980-8. PubMed ID: 18428149 [TBL] [Abstract][Full Text] [Related]
4. Immune responses in hepatitis C virus infection and mechanisms of hepatitis C virus persistence. Hiroishi K; Ito T; Imawari M J Gastroenterol Hepatol; 2008 Oct; 23(10):1473-82. PubMed ID: 18761560 [TBL] [Abstract][Full Text] [Related]
5. Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment. Gonzalez VD; Falconer K; Björkström NK; Blom KG; Weiland O; Ljunggren HG; Alaeus A; Sandberg JK J Immunol; 2009 Nov; 183(10):6612-8. PubMed ID: 19846870 [TBL] [Abstract][Full Text] [Related]
7. Ribavirin in the treatment of hepatitis C. Abonyi ME; Lakatos PL Anticancer Res; 2005; 25(2B):1315-20. PubMed ID: 15865084 [TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus (HCV): a review of immunological aspects. Irshad M; Khushboo I; Singh S; Singh S Int Rev Immunol; 2008; 27(6):497-517. PubMed ID: 19065353 [TBL] [Abstract][Full Text] [Related]
9. Chronic hepatitis C virus infection in renal transplant: treatment and outcome. Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715 [TBL] [Abstract][Full Text] [Related]
10. Quantification and functional analysis of plasmacytoid dendritic cells in patients with chronic hepatitis C virus infection. Goutagny N; Vieux C; Decullier E; Ligeoix B; Epstein A; Trepo C; Couzigou P; Inchauspe G; Bain C J Infect Dis; 2004 May; 189(9):1646-55. PubMed ID: 15116301 [TBL] [Abstract][Full Text] [Related]
11. Natural killer cell activity and function in chronic HCV-infected patients during peg interferon and ribavirin: early effects of active substance use. Hotho DM; Kreefft K; Groothuismink ZM; Janssen HL; de Knegt RJ; Boonstra A Antiviral Res; 2013 Mar; 97(3):347-55. PubMed ID: 23291200 [TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus (HCV) employs multiple strategies to subvert the host innate antiviral response. Bode JG; Brenndörfer ED; Häussinger D Biol Chem; 2008 Oct; 389(10):1283-98. PubMed ID: 18713016 [TBL] [Abstract][Full Text] [Related]
13. Dendritic cell inhibition is connected to exhaustion of CD8+ T cell polyfunctionality during chronic hepatitis C virus infection. Rodrigue-Gervais IG; Rigsby H; Jouan L; Sauvé D; Sékaly RP; Willems B; Lamarre D J Immunol; 2010 Mar; 184(6):3134-44. PubMed ID: 20173023 [TBL] [Abstract][Full Text] [Related]
14. Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment. Urbani S; Amadei B; Tola D; Pedrazzi G; Sacchelli L; Cavallo MC; Orlandini A; Missale G; Ferrari C J Hepatol; 2008 Apr; 48(4):548-58. PubMed ID: 18280607 [TBL] [Abstract][Full Text] [Related]
16. The clinical and immunologic impact of using interferon and ribavirin in the immunosuppressed host. Braun M; Vierling JM Liver Transpl; 2003 Nov; 9(11):S79-89. PubMed ID: 14586901 [TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin. Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081 [TBL] [Abstract][Full Text] [Related]
18. Antibodies against hepatitis C virus-like particles and viral clearance in acute and chronic hepatitis C. Baumert TF; Wellnitz S; Aono S; Satoi J; Herion D; Tilman Gerlach J; Pape GR; Lau JY; Hoofnagle JH; Blum HE; Liang TJ Hepatology; 2000 Sep; 32(3):610-7. PubMed ID: 10960457 [TBL] [Abstract][Full Text] [Related]
19. Impaired ability of interferon-alpha-primed dendritic cells to stimulate Th1-type CD4 T-cell response in chronic hepatitis C virus infection. Miyatake H; Kanto T; Inoue M; Sakakibara M; Kaimori A; Yakushijin T; Itose I; Miyazaki M; Kuzushita N; Hiramatsu N; Takehara T; Kasahara A; Hayashi N J Viral Hepat; 2007 Jun; 14(6):404-12. PubMed ID: 17501761 [TBL] [Abstract][Full Text] [Related]
20. Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients. Decalf J; Fernandes S; Longman R; Ahloulay M; Audat F; Lefrerre F; Rice CM; Pol S; Albert ML J Exp Med; 2007 Oct; 204(10):2423-37. PubMed ID: 17893202 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]